Abstract
The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Current Computer-Aided Drug Design
Title:Structure-Based Development of Antagonists for Chemokine Receptor CXCR4
Volume: 9 Issue: 1
Author(s): Chongqian Zhang, Tingjun Hou, Zhiwei Feng and Youyong Li
Affiliation:
Keywords: CXCR4, crystal structure, anti-HIV-1 inhibitors, DOCK, molecular dynamics, SAR, drug development, critical residues, chemokine receptor, antagonist
Abstract: The C-X-C chemokine receptor-4(CXCR4) is a G-protein coupled receptor (GPCR) which belongs to the family I GPCR or rhodopin-like GPCR family. CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane, and is implicated in cancer metastasis and inflammation. Recently, crystal structure of human CXCR4 receptor was reported, which facilitates the structure-based drug discovery of CXCR4 significantly. Here we summarize the structure feature of C-X-C chemokine and its difference from other rhodopsin-like GPCR family, the impact of recent crystal structure on CXCR4 drug development, the available active compounds for CXCR4 receptor, SAR studies of the available active compounds, the recognition mechanism of the inhibitors of CXCR4 receptor (molecular docking results and molecular dynamics results), which illustrates the interaction between the inhibitors and critical residues of CXCR4, and the outlook of drug development for CXCR4 receptor.
Export Options
About this article
Cite this article as:
Zhang Chongqian, Hou Tingjun, Feng Zhiwei and Li Youyong, Structure-Based Development of Antagonists for Chemokine Receptor CXCR4, Current Computer-Aided Drug Design 2013; 9 (1) . https://dx.doi.org/10.2174/1573409911309010006
DOI https://dx.doi.org/10.2174/1573409911309010006 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors
Current Enzyme Inhibition Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review
Current Medicinal Chemistry Natural Products for Fungal Diseases Management and Prevention
The Natural Products Journal Regulation of MAPK Signaling Pathways Through Immunophilin-ligand Complex
Current Topics in Medicinal Chemistry ER Stress and UPR in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine New Perspectives in the Management of Secondary Hyperparathyroidism
Mini-Reviews in Medicinal Chemistry Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Male Fertility-Implications of Anticancer Treatment and Strategies to Mitigate Gonadotoxicity
Anti-Cancer Agents in Medicinal Chemistry Investigation of <i>ACE rs4646994, MTHFR rs1801133</i> and <i>VDR rs2228570</i> Genotypes in Jordanian Patients with Fibromyalgia Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design A Review of Current Strategies for Treatment Resistant Obsessive-Compulsive Disorder
Current Drug Therapy Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Uric Acid and the Kidney: Urate Transport, Stone Disease and Progressive Renal Failure
Current Pharmaceutical Design Gene Expression Signatures in Primary Immunodeficiencies: The Experience from Human Disease and Mouse Models
Current Molecular Medicine PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Current Pharmaceutical Design Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Fishing Anti-Inflammatories from Known Drugs: In Silico Repurposing, Design, Synthesis and Biological Evaluation of Bisacodyl Analogues
Current Topics in Medicinal Chemistry